BioSpace News Archive

Defence Therapeutics Inc. is pleased to announce the publication of a peer-reviewed study on the anticancer properties of its dual Accum®-E7 vaccine, one of Defence’s experimental product designed to treat established cervical cancer.

- ACG Capsules Pithampur, India is ACG’s 1st lighthouse to join the community.

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia’s common stock on February 29, 2024, as an inducement material to such employee entering into employment with Akebia.

ORIC Pharmaceuticals, Inc. announced that on March 1, 2024, ORIC granted a total of 3,600 non-qualified stock options and 600 restricted stock units to one new non-executive employee who began their employment with ORIC in February 2024.

Kura Oncology, Inc. announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase 93,000 shares of common stock to two new employees under the Company’s 2023 Inducement Option Plan.

Taysha Gene Therapies, Inc. announced that, on March 1, 2024, the Compensation Committee of Taysha’s Board of Directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the Company’s common stock in connection with their employment.

Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial.

Zentalis® Pharmaceuticals, Inc. announced that on March 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 125,000 shares of the Company’s common stock to two newly hired employees.

BioNxt Solutions Inc. is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis has been completed.